The atezolizumab market comprises PD-L1 inhibitors such as atezolizumab, avelumab and durvalumab that act as immune checkpoint inhibitors. These inhibitors play a vital role in cancer immunotherapy as they help boost the immune system's ability to fight cancer cells. Atezolizumab is a targeted immunotherapy treatment approved for use in several types of cancer including bladder cancer, lung...
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian